FMP
Aurinia Pharmaceuticals Inc.
AUPH
NASDAQ
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
9.03 USD
-0.01 (-0.111%)
About
ceo
Mr. Peter S. Greenleaf M.B.A.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
CIK
0001600620
ISIN
CA05156V1022
CUSIP
05156V102
Address
4464 Markham Street
Phone
12507084272
Country
CA
Employee
300
IPO Date
Sep 3, 2014
Key Executives
